Prelude Therapeutics Future Growth
Future criteria checks 2/6
Prelude Therapeutics's earnings are forecast to decline at 7.1% per annum while its annual revenue is expected to grow at 60.4% per year. EPS is expected to grow by 8.5% per annum.
Key information
-7.1%
Earnings growth rate
8.5%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | 60.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 12 Dec 2024 |
Recent future growth updates
Recent updates
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Sep 16
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 09Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data
Feb 03Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Sep 17We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 28Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Jan 28We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely
Oct 27Prelude wins FDA clearance to start Phase 1 trial for cancer candidate
Oct 18Prelude downgraded at Morgan Stanley ahead of key update
Sep 09We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Jun 28Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Mar 14We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth
Dec 14Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Jul 05What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?
Feb 16
Prelude Therapeutics prices $150M share offering
Jan 07Prelude Therapeutics readies public offering
Jan 04Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares
Dec 25Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -162 | -136 | N/A | 2 |
| 12/31/2025 | N/A | -153 | -132 | N/A | 3 |
| 12/31/2024 | 2 | -136 | -125 | N/A | 4 |
| 9/30/2024 | 3 | -132 | -108 | -106 | N/A |
| 6/30/2024 | N/A | -130 | -106 | -104 | N/A |
| 3/31/2024 | N/A | -126 | -112 | -109 | N/A |
| 12/31/2023 | N/A | -122 | -111 | -107 | N/A |
| 9/30/2023 | N/A | -117 | -109 | -106 | N/A |
| 6/30/2023 | N/A | -117 | -104 | -101 | N/A |
| 3/31/2023 | N/A | -114 | -95 | -92 | N/A |
| 12/31/2022 | N/A | -115 | -87 | -84 | N/A |
| 9/30/2022 | N/A | -120 | -89 | -87 | N/A |
| 6/30/2022 | N/A | -120 | -91 | -88 | N/A |
| 3/31/2022 | N/A | -120 | -92 | -89 | N/A |
| 12/31/2021 | N/A | -112 | -86 | -84 | N/A |
| 9/30/2021 | N/A | -98 | -75 | -73 | N/A |
| 6/30/2021 | N/A | -84 | -65 | -63 | N/A |
| 3/31/2021 | N/A | -69 | -54 | -52 | N/A |
| 12/31/2020 | N/A | -57 | -47 | -46 | N/A |
| 9/30/2020 | N/A | -48 | -40 | -40 | N/A |
| 6/30/2020 | N/A | -38 | -34 | -33 | N/A |
| 3/31/2020 | N/A | -32 | -31 | -30 | N/A |
| 12/31/2019 | N/A | -28 | -26 | -26 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRLD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PRLD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PRLD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PRLD's revenue (60.4% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: PRLD's revenue (60.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PRLD's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 12:07 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Prelude Therapeutics Incorporated is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Tazeen Ahmad | BofA Global Research |
| Graig Suvannavejh | Goldman Sachs |